Radiotheranostics and the Future of Cancer Therapy: Harnessing Combination Strategies and AI

Abstract

Radiotheranostics, defined as the subset of theranostics wherein both diagnostic imaging and therapeutic functions are specifically enabled by radionuclides, represents a transformative advancement in precision oncology, integrating diagnostic imaging and targeted radionuclide therapy within a single molecular platform. Through coupling radionuclides with highly specific vectors such as antibodies, peptides, or small molecules, this approach enables selective delivery of radiation to tumor sites expressing biomarkers such as prostate-specific membrane antigen (PSMA) and human epidermal growth factor receptor 2 (HER2), thereby maximizing tumor cytotoxicity while sparing healthy tissue. Radiopharmaceuticals are engineered through meticulous radionuclide selection (e.g., Lutetium-177 (¹⁷⁷Lu) or Actinium-225 (²²⁵Ac)) as well as optimized carrier systems that influence biodistribution, targeting efficiency, and clearance kinetics. Imaging modalities such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) aid in patient selection, dosimetry, and real-time visualization of therapeutic efficacy. In clinical studies, radiopharmaceuticals have exhibited efficacy across multiple cancers, including prostate, neuroendocrine, breast, and ovarian malignancies. Beyond direct DNA damage, these agents can stimulate immunogenic cell death, boosting anti-tumor immunity. Combining radiopharmaceuticals with immunotherapy, chemotherapy, or PARP inhibitors may offer benefits over standard of care. Further, integration of Artificial Intelligence (AI) into radiotherapy (RT) workflows can potentially revolutionize treatment planning, contouring, adaptive dose management, and predictive modeling. Collectively, radiotheranostics exemplifies evolution of cancer management toward a highly personalized paradigm, combining molecular targeting, multimodal imaging, and AI-driven optimization. As ongoing research refines carrier systems, expands the repertoire of radionuclides, and enhances combinatorial strategies, radiotheranostics remains at the forefront of next-generation cancer therapeutics.

Keywords: Radiotheranostics, Targeted Radiopharmaceuticals, Precision Oncology, Molecular Imaging, Artificial Intelligence Integration